Overview

A class action lawsuit has been filed against Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ : CORT) and certain of the Company’s senior executive officers alleging violations of the federal securities laws. The Corcept lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”). Investors have until April 21, 2026, to seek appointment as lead plaintiff of the Corcept class action lawsuit.

Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. One of its lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as “Cushing’s syndrome”).

The complaint alleges that Defendants failed to disclose that the FDA had told Corcept that it had concerns about the adequacy of the program assessing relacorilant’s effectiveness in treating hypertension in patients with hypercortisolism, including the design of the GRACE clinical trial. The FDA had further told Corcept to expect significant issues with the review if Corcept was to submit the new drug application (“NDA”). As a result, Defendants’ positive statements concerning their interactions with the FDA and their expectations that the relacorilant NDA would be approved, were materially false or misleading.

On December 31, 2025, Corcept revealed that the FDA had issued an unfavorable Complete Response Letter (“CRL”) regarding the NDA for relacorilant. Specifically, the Company stated that “the [FDA] concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.” In the press release announcing that it had received the CRL, Corcept stated that “[w]e are surprised and disappointed by this outcome.”

On this news, the price of Corcept common stock declined by $35.40 per share, or 50%, from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025.

*          *          *

If you purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, and you wish to serve as lead plaintiff in this lawsuit, you are encouraged to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt attorneys Brian O’Mara and Hani Farah by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the Corcept class action lawsuit is April 21, 2026.